Pharmaspire
× About the Journal Scope of the Journal SPER Publications Editorial Board Abstracting and Indexing Articles in Press Current Issue Archives Submit Article Author Guidelines Advertise Join as Reviewer Contact Editorial Policies and Peer Review Process Journal Policies Publishing Ethics
[An Official Publication of ISF College of Pharmacy, Moga]


 

Original Article
Year : 2019   |  Volume : 11  |  Issue : 2  |  Page : 51-62

Role of phosphoinositide-3-kinase/AKT activation mediated by inhibition of protein tyrosine phosphate-1B inhibitor in cardioprotection

Background: Dyslipidemia is a downregulator of phosphoinositide-3-kinase (PI3K)/AKT-mediated cell survival pathway and reduces the preconditioning potential in ischemic-reperfusion (I/R) injured rat heart ultimately leads to cardiac cell death. Objective: The present study was designed to explore and confirm the pharmacological perspective of sodium orthovanadate (SOV), an inhibitor of tyrosine phosphate-1B protein against ischemic-reperfusion (I/R) injury in dyslipidemic rat. Martials and Methods: The dyslipidemic rodent hearts were isolated and fixed on Langendorff’s device, exposed to 30 miniature reperfusion. Ischemic preconditioning was started by four episodes of 5 min ischemia and 5 min reperfusion. Infarction was assessed using triphenyltetrazolium chloride staining, and coronary effluent was inspected for lactate dehydrogenase (LDH) and creatinine kinase-MB discharge to decide the degree of myocardial damage. The cardiac discharge of nitric oxide (NO) was assessed by determining the discharge of nitrite in coronary emission. Results: Pharmacological preconditioning with SOV significantly re-imposed I/R mediated myocardial infarction in dyslipidemic rat heart when compared with dyslipidemic and I/R control group. In this study, the statistical data show the significant values P < 0.05. However, in observed results, cardioprotection was abolished by perfusion of BEZ-235, a PI3K/AKT pathway inhibitor noted in terms of myocardial injury events such as a rise in myocardial infarct mass, tumor necrosis factor-alpha, LDH, CK-MB, and also decrease in the release of NO. Conclusion: Hence, it stated that SOV repairs impaired cardioprotective effect in dyslipidemic rat heart maybe because of activation of the PI3K/AKT cell survival pathway which was confirmed using PI3K/AKT inhibitor BEZ-235.
[]*
Print this article     Email this article

 

Contact SPER Publications


SPER Publications and Solutions Pvt. Ltd.

#730, Tower B, i-Thum IT Park,
Sector 62, Noida,
Uttar Pradesh 201301 [Delhi-NCR] India
Phone: +91-930-190-7999 / +91-120-410-0035
E-mail: journals@sperpublications.com
Website: www.sperpublications.com